F-1/A: Cuprina Holdings Eyes Nasdaq Listing with 3.75 Million Share IPO

Cuprina Holdings, a Singapore-based biomedical firm, plans to raise capital through an initial public offering of 3.75 million Class A Ordinary Shares on the Nasdaq Capital Market.

Summary

• Cuprina Holdings (Cayman) Limited is planning an initial public offering of 3,750,000 Class A Ordinary Shares.
• The expected IPO price is between US$4.00 and US$4.50 per share.
• The company has applied to list its Class A Ordinary Shares on the Nasdaq Capital Market under the symbol CUPR.
• The offering's closing is contingent upon Nasdaq's final approval.
• Immediately after the offering, the company will have 3,915,000 Class A Ordinary Shares and 14,085,000 Class B Ordinary Shares outstanding.
• Class B shares have 10 votes each and are convertible to Class A shares.
• Cuprina Holding Pte. Ltd. will control over 50% of the voting power post-IPO, making Cuprina Holdings a controlled company.
• The company is an emerging growth company and a foreign private issuer, entitling it to reduced reporting requirements.
• Cuprina intends to use approximately 46.7% (US$6.2 million) of the net proceeds for growth and expansion into new markets.
• Approximately 12.8% (US$1.7 million) is earmarked for research and development, and 8.6% (US$1.1 million) each for building brand awareness and investing in equipment and infrastructure.
• A portion of the proceeds, 6.3% (US$0.8 million), will be used to repay a loan to an ultimate beneficial shareholder.
• The remaining net proceeds will be used for working capital and general corporate purposes.
• Network 1 Financial Securities, Inc. is the underwriter for the offering and will receive warrants to purchase 5% of the Class A Ordinary Shares sold.
• The underwriters also have a 45-day option to purchase up to 562,500 additional Class A Ordinary Shares to cover over-allotments.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is pursuing growth opportunities and has innovative products, it also faces financial challenges and risks associated with its early-stage status and competitive industry.

Positives

• The company has strategic plans to expand sales and establish physical operations in Southeast Asia, the Middle East, and mainland China.
• The company has attained ISO 13485:2016 standards for its manufacturing facility in Singapore.
• The company is working towards obtaining compliance with 21 CFR Part 820 to secure FDA 510(k) clearance for its chronic wound care products.
• The company has access to innovative technology in developing pipeline products through collaborations with research universities.
• The company is committed to sustainability, focusing on developing products from natural sources and valorizing waste streams.

Negatives

• The company has a history of losses, with a net loss of S$1,119,555 (US$849,048) in 2023.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023, and such positions may continue after this offering.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company relies on certain agreements entered between NTU and us to develop and sell certain of our pipeline products, including products incorporating bullfrog collagen.
• The company's maggot-based chronic wound care products are not currently protected by any pending patent application nor any unexpired patent.

Risks

• The company is an early-stage company with a history of losses and expects to incur losses in the future.
• The company's business relies on industry development and consumer demand for its products.
• The company's revenue growth is difficult to predict, and a shortfall in forecasted revenues may harm operating results.
• The company recorded net current liabilities as of December 31, 2021, 2022 and 2023, and such positions may continue after this offering.
• The company had net operating cash outflows for the years ended December 31, 2021, 2022 and 2023.
• The company may not be able to develop new products that are competitive or successful in the markets it has entered or plans to enter, in a timely manner or at all.
• The development and sale of certain of the company's pipeline products are heavily dependent on certain agreements with NTU and the termination of any of these agreements could harm the company's business.
• Certain of the company's pipeline products are still under development and the company may not be able to successfully commercialize any of these product candidates.
• An active trading market for the company's Class A Ordinary Shares may not be established or, if established, may not continue and the trading price for the company's Class A Ordinary Shares may fluctuate significantly.
• The company may not maintain the listing of its Class A Ordinary Shares on the Nasdaq which could limit investors ability to make transactions in Class A Ordinary Shares and subject the company to additional trading restrictions.
• The trading price of the company's Class A Ordinary Shares may be volatile, which could result in substantial losses to investors.
• The dual-class structure of the company's ordinary shares may adversely affect the trading market for its Class A Ordinary Shares.
• The sale or availability for sale of substantial amounts of the company's Class A Ordinary Shares could adversely affect their market price.
• The company will be a controlled company within the meaning of the rules of Nasdaq and, as a result, will rely on exemptions from certain corporate governance requirements that provide protection to shareholders of other companies.

Future Outlook

The company plans to expand into new geographic markets, continue to expand its product portfolio through development and innovation, strengthen brand awareness, and acquire and retain customers.

Industry Context

The company operates in the biomedical and biotechnology sectors, focusing on chronic wound care and cosmeceuticals, which are experiencing growth due to an aging population and increased prevalence of comorbidities.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• To make a comparison, specific details about the company's financial performance, such as gross margins, operating expenses, and R&D spending as a percentage of revenue, would need to be compared to those of its competitors.
• Some of the major players in the wound care market include Smith & Nephew, ConvaTec, and Mlnlycke Health Care.
• Comparing Cuprina's financial metrics to these companies would provide a better understanding of its performance relative to industry standards.

Related Party Transactions

• The company has engaged in transactions with related parties, including loans from shareholders and management fees paid to related companies.
• Cuprina Holding Pte. Ltd. provided advances to the company for working capital purposes.
• Jimmy Lee Peng Siew, an ultimate beneficial owner, provided advances to the company for working capital purposes.
• The company has a joint venture agreement with a local medical services company in Saudi Arabia.
• The company has a collaboration agreement with Nanao (Beijing) Hospital Management Co., Ltd. for product registration in mainland China.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the IPO and the dual-class share structure.
• Employees may be impacted by the company's ability to manage growth and retain talent.
• Customers may benefit from the company's expansion into new markets and development of new products.
• Suppliers may benefit from increased orders as the company grows.

Next Steps

• The company needs to secure final approval from Nasdaq for its listing application.
• The company plans to expand into new geographic markets, including Southeast Asia, the Middle East, and mainland China.
• The company plans to continue research and development activities to expand its product offerings.
• The company plans to build brand awareness through marketing activities.

Key Dates

Keywords

IPO, Class A Ordinary Shares, Cuprina Holdings, Nasdaq, Biomedical, Biotechnology, Wound Care, MEDIFLY, Cosmeceuticals, Emerging Growth Company